JP2011506492A5 - - Google Patents

Download PDF

Info

Publication number
JP2011506492A5
JP2011506492A5 JP2010538291A JP2010538291A JP2011506492A5 JP 2011506492 A5 JP2011506492 A5 JP 2011506492A5 JP 2010538291 A JP2010538291 A JP 2010538291A JP 2010538291 A JP2010538291 A JP 2010538291A JP 2011506492 A5 JP2011506492 A5 JP 2011506492A5
Authority
JP
Japan
Prior art keywords
gemcitabine
composition according
compound
erlotinib
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010538291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506492A (ja
JP5473937B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2008/002190 external-priority patent/WO2009076761A1/en
Publication of JP2011506492A publication Critical patent/JP2011506492A/ja
Publication of JP2011506492A5 publication Critical patent/JP2011506492A5/ja
Application granted granted Critical
Publication of JP5473937B2 publication Critical patent/JP5473937B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010538291A 2007-12-19 2008-12-18 膵臓癌の治療のためのゲムシタビンと併用した中鎖脂肪酸、その塩およびトリグリセリド Expired - Fee Related JP5473937B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US812907P 2007-12-19 2007-12-19
US61/008,129 2007-12-19
PCT/CA2008/002190 WO2009076761A1 (en) 2007-12-19 2008-12-18 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer

Publications (3)

Publication Number Publication Date
JP2011506492A JP2011506492A (ja) 2011-03-03
JP2011506492A5 true JP2011506492A5 (enExample) 2012-02-02
JP5473937B2 JP5473937B2 (ja) 2014-04-16

Family

ID=40795145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010538291A Expired - Fee Related JP5473937B2 (ja) 2007-12-19 2008-12-18 膵臓癌の治療のためのゲムシタビンと併用した中鎖脂肪酸、その塩およびトリグリセリド

Country Status (15)

Country Link
US (1) US8946190B2 (enExample)
EP (1) EP2231166B1 (enExample)
JP (1) JP5473937B2 (enExample)
KR (1) KR101603351B1 (enExample)
CN (1) CN101903028B (enExample)
AU (1) AU2008338204B2 (enExample)
BR (1) BRPI0821395A2 (enExample)
CA (1) CA2708679C (enExample)
DK (1) DK2231166T3 (enExample)
ES (1) ES2414617T3 (enExample)
MX (1) MX2010006867A (enExample)
NZ (1) NZ586249A (enExample)
PT (1) PT2231166E (enExample)
TW (1) TWI448290B (enExample)
WO (1) WO2009076761A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2427416B1 (en) 2009-05-04 2016-03-09 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical uses thereof
CN105997967B (zh) 2010-10-27 2019-08-23 普罗米蒂克医药Smt有限公司 用于治疗癌症的化合物和组合物
CN102617679B (zh) * 2012-03-13 2014-11-26 北京大学 一种共轭亚油酸与吉西他滨连接的前体药物制备方法及其应用
WO2014126969A1 (en) * 2013-02-12 2014-08-21 Bend Research, Inc. Solid dispersions of low-water solubility actives
US9737538B2 (en) 2013-02-12 2017-08-22 Bend Research, Inc. Solid dispersions of low-water solubility actives
US11351139B2 (en) 2013-02-28 2022-06-07 Basf As Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
US10463684B2 (en) 2014-01-29 2019-11-05 Board Of Regents, The Uneversety Of Texas System Nucleobase analogue derivatives and their applications
MA53188A1 (fr) 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68928756T2 (de) * 1989-03-13 1999-03-04 Cellegy Pharma Inc Topische Zubereitungen enthaltend aliphatische Amine zur Behandlung von Hautkrankheiten
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
DK1900364T3 (da) * 2001-04-18 2014-01-13 Prometic Biosciences Inc Fedtsyrer, glycerider og analoger med medium kædelængde som neutrofile overlevelses- og aktiveringsfaktorer
JP2005507874A (ja) * 2001-08-29 2005-03-24 ユーエムディー, インコーポレイテッド 癌治療のための化学療法剤及び膜流出システム阻害剤の経膣送達
US20060012880A1 (en) * 2002-05-02 2006-01-19 Law Benjamin P Optical device with refractive and diffractive properties
BRPI0407276A (pt) * 2003-02-07 2006-01-31 Prometic Biosciences Inc ácidos graxos, glicerìdeos e análogos com comprimento de cadeia médio, como estimulantes de eritropoiese
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.

Similar Documents

Publication Publication Date Title
JP2012512907A5 (enExample)
JP2009535462A5 (enExample)
JP2009530399A5 (enExample)
JP2011518833A5 (enExample)
JP2013537905A5 (enExample)
JP2010500343A5 (enExample)
JP2013518107A5 (enExample)
ME02321B (me) Antivirusna jedinjenja
JP2012144574A5 (enExample)
JP2007302689A5 (enExample)
JP2019511491A5 (enExample)
JP2011527332A5 (enExample)
JP2010077141A5 (enExample)
JP2010522791A5 (enExample)
RU2012118974A (ru) Комбинации ингибитора pi3k и ингибитора мек
JP2013510885A5 (enExample)
JP2006143746A5 (enExample)
JP2014500861A5 (enExample)
JP2012532883A5 (enExample)
JP2012504619A5 (enExample)
JP2014519507A5 (enExample)
JP2012522841A5 (enExample)
JP2012509265A5 (enExample)
JP2011527678A5 (enExample)
JP2009513604A5 (enExample)